Yesterday, Transgenomic, Inc. announced that it has welcomed Katherine A. Richardson, Ph.D. as its new Technical Director for Laboratory Services. As part of her responsibilities, Dr. Richardson will manage the day-to-day operations of Transgenomic’s Laboratory Services labs, and will report to Craig Tuttle, Transgenomic’s president and CEO.
“Dr. Richardson has an impressive background and we are pleased to welcome her to Transgenomic,” said Mr. Tuttle. “She clearly has the stature and expertise in the scientific community we are looking for as we further develop our laboratory services business as well as very strong ties to pharmaceutical research which should help us further expand our Pharmacogenomics services business. Dr. Richardson has to her credit nearly 60 publications, abstracts and presentations at scientific conferences, and she was part of the group at Eli Lilly that identified the link between the BRCA-1 gene and hereditary breast cancer. In particular, we look forward to tapping Dr. Richardson’s extensive experience in pharmaceutical drug development and companion diagnostic testing as well as in regulatory and laboratory operating procedures.”
With her appointment, Dr. Richardson brings over 25 years of genetic laboratory experience. Prior to Transgenomic she spent eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Previously Dr. Richardson was with Eli Lilly and Company for nine years as a senior toxicologist specializing in genetic toxicology and molecular carcinogenesis.
Dr. Richardson holds a S.B. degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular cellular developmental biology from Iowa State University.